Closed

Anti-MAGE-A12 (KMAELVHFL) T cell receptor, pCDTCR1 (TCR-C116Z)

The vector of anti-MAGE-A12 T cell receptor (TCR) is constructed for the engineering of T cell to target Human MAGE-A12. The T cells are genetically modified through transduction with a lentiviral vector expressing MAGE-A12-specific T cell receptor. And the vector product was designed for the treatment of Melanoma.

Details

  • Target
  • MAGE-A12
  • Target Species
  • Human
  • Epitope
  • KMAELVHFL
  • Format
  • Non-modified
  • HLA
  • HLA-A*0201
  • Targeting Diseases
  • Melanoma
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral
  • Antibody Host
  • Mouse

Target

  • Gene Name
  • MAGE family member A12
  • Official Symbol
  • MAGEA12
  • Synonyms
  • MAGEA3; Cancer/Testis Antigen Family 1, Member 3; Cancer/Testis Antigen Family 1; MAGE3; MAGEA6; Antigen MZ2-D; Melanoma-Associated Antigen 3; Melanoma Antigen Family A, 3; TCR; T cell receptor; transgenic TCR; antigen-specific T cell receptors; Engineering T-cell receptors; recombinant t cell receptors; specific t cell receptor; modified t cell receptor; retroviral vector; Melanoma
  • Introduction
  • This gene is closely related to several other genes clustered on chromosome X. These genes may be overexpressed in tumors. Multiple alternatively spliced variants encoding the same protein have been identified.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry
Products

CONTACT US

45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Email:

Online Inquiry

For any technical issues or products/services related questions, please leave your contacts as below, and our team will contact you at earliest convenience to let you know how we can be involved in your projects.

  • Verification code

Key Updates

Receive the latest news and insights to your inbox.